ArticleInfection2026
Candida endocarditis in the United States: contemporary clinical predictors of mortality from a nationwide analysis (2016-2022).
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandida endocarditis (CE) is a rare but highly lethal complication of candidemia, comprising 1-2% of infective endocarditis cases, yet associated with disproportionately high mortality. Large-scale contemporary data on predictors of in-hospital death remain limited.
methodsWe conducted a retrospective cohort study using the National Inpatient Sample (2016-2022) to identify adult CE hospitalizations. Weighted descriptive statistics described the cohort, and multivariable logistic regression identified predictors of in-hospital mortality. Secondary outcomes included length of stay (LOS) and hospitalization costs.
resultsAmong 1280 CE hospitalizations, in-hospital mortality was 18.8%. Predictors of higher mortality included age 45-64 years (aOR 2.61; 95% CI 1.57-4.41) and ≥ 75 years (aOR 2.11; 95% CI 1.06-4.19), hematologic malignancy (aOR 33.5; 95% CI 12.3-101), surgical ventricular assist devices (aOR 45.7; 95% CI 8.25-284), femoral (aOR 12.9; 95% CI 4.78-36.0) or subclavian (aOR 22.4; 95% CI 5.65-82.7) central venous catheters, septic shock (aOR 9.47; 95% CI 6.21-14.8), embolic stroke (aOR 10.5; 95% CI 4.72-23.9), cardiogenic shock (aOR 3.69; 95% CI 1.61-8.51), and acute kidney injury (aOR 1.64; 95% CI 1.04-2.60). Valve intervention significantly reduced mortality (aOR 0.04; 95% CI 0.01-0.09). Non-survivors had longer hospital stays (median 24 vs. 19 days) and nearly double the hospitalization costs ($117,808 vs. $61,178).
conclusionsIn this nationally representative cohort, CE remained highly lethal, with age, malignancy, invasive devices, and critical complications driving mortality. Valve intervention conferred substantial survival benefit, underscoring the importance of early recognition, multidisciplinary care, and timely surgical evaluation.
Indexed as
Identifiers
41784858What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.